IL130979A0 - An aqueous suspension for nasal admnistration containing loteprednol etabonate and microcrystalline cellulose carmellose sodium - Google Patents

An aqueous suspension for nasal admnistration containing loteprednol etabonate and microcrystalline cellulose carmellose sodium

Info

Publication number
IL130979A0
IL130979A0 IL13097998A IL13097998A IL130979A0 IL 130979 A0 IL130979 A0 IL 130979A0 IL 13097998 A IL13097998 A IL 13097998A IL 13097998 A IL13097998 A IL 13097998A IL 130979 A0 IL130979 A0 IL 130979A0
Authority
IL
Israel
Prior art keywords
admnistration
nasal
microcrystalline cellulose
aqueous suspension
loteprednol etabonate
Prior art date
Application number
IL13097998A
Other languages
English (en)
Original Assignee
Nicholas Bodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Bodor filed Critical Nicholas Bodor
Publication of IL130979A0 publication Critical patent/IL130979A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL13097998A 1997-01-16 1998-01-14 An aqueous suspension for nasal admnistration containing loteprednol etabonate and microcrystalline cellulose carmellose sodium IL130979A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1966497 1997-01-16
PCT/JP1998/000108 WO1998031343A2 (en) 1997-01-16 1998-01-14 Aqueous suspension for nasal administration of loteprednol

Publications (1)

Publication Number Publication Date
IL130979A0 true IL130979A0 (en) 2001-01-28

Family

ID=12005518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13097998A IL130979A0 (en) 1997-01-16 1998-01-14 An aqueous suspension for nasal admnistration containing loteprednol etabonate and microcrystalline cellulose carmellose sodium

Country Status (32)

Country Link
US (1) US6368616B1 (lt)
EP (1) EP0973501B1 (lt)
KR (1) KR100471708B1 (lt)
CN (1) CN1126535C (lt)
AR (1) AR011773A1 (lt)
AT (1) ATE249205T1 (lt)
AU (1) AU730953C (lt)
BR (1) BR9806771A (lt)
CA (1) CA2278025C (lt)
CZ (1) CZ294919B6 (lt)
DE (1) DE69818026T2 (lt)
DK (1) DK0973501T3 (lt)
EA (1) EA001775B1 (lt)
ES (1) ES2206880T3 (lt)
HU (1) HU226613B1 (lt)
ID (1) ID21892A (lt)
IL (1) IL130979A0 (lt)
LT (1) LT4677B (lt)
LV (1) LV12449B (lt)
MX (1) MXPA99006628A (lt)
NO (1) NO324619B1 (lt)
NZ (2) NZ509908A (lt)
PL (1) PL190753B1 (lt)
PT (1) PT973501E (lt)
RS (1) RS49701B (lt)
SI (1) SI20057A (lt)
SK (1) SK283164B6 (lt)
TR (1) TR199901663T2 (lt)
TW (1) TW503113B (lt)
UA (1) UA52722C2 (lt)
WO (1) WO1998031343A2 (lt)
ZA (1) ZA98303B (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
AU762145C (en) 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
IL159415A0 (en) * 2001-06-18 2004-06-01 Noven Pharma Enhanced drug delivery in transdermal systems
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
WO2005000317A1 (en) 2003-06-19 2005-01-06 Bodor Nicholas S Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
EP1658083B1 (en) * 2003-06-19 2007-08-08 BODOR, Nicholas S. Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
ATE441419T1 (de) 2004-03-25 2009-09-15 Bausch & Lomb Verwendung von loteprednoletabonat zur behanldung von trockenen augen
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액

Also Published As

Publication number Publication date
DK0973501T3 (da) 2004-01-19
EP0973501B1 (en) 2003-09-10
CN1126535C (zh) 2003-11-05
UA52722C2 (uk) 2003-01-15
AR011773A1 (es) 2000-09-13
SI20057A (sl) 2000-04-30
TR199901663T2 (xx) 1999-09-21
MXPA99006628A (es) 2005-01-10
ZA98303B (en) 1998-07-20
ATE249205T1 (de) 2003-09-15
NO993453L (no) 1999-07-13
AU730953B2 (en) 2001-03-22
SK94899A3 (en) 2000-05-16
LT4677B (lt) 2000-07-25
AU5495298A (en) 1998-08-07
PT973501E (pt) 2004-02-27
BR9806771A (pt) 2000-05-16
NZ509908A (en) 2004-12-24
EP0973501A2 (en) 2000-01-26
CZ294919B6 (cs) 2005-04-13
EA199900659A1 (ru) 2000-02-28
NZ336990A (en) 2001-03-30
NO324619B1 (no) 2007-11-26
ES2206880T3 (es) 2004-05-16
LT99100A (lt) 2000-02-25
HU226613B1 (en) 2009-04-28
CA2278025A1 (en) 1998-07-23
WO1998031343A3 (en) 1998-09-17
YU36199A (sh) 2002-09-19
EA001775B1 (ru) 2001-08-27
KR100471708B1 (ko) 2005-03-07
HUP0002473A3 (en) 2001-01-29
LV12449B (en) 2000-09-20
NO993453D0 (no) 1999-07-13
CN1250370A (zh) 2000-04-12
TW503113B (en) 2002-09-21
PL334614A1 (en) 2000-03-13
DE69818026D1 (de) 2003-10-16
AU730953C (en) 2002-02-07
DE69818026T2 (de) 2004-07-08
SK283164B6 (sk) 2003-03-04
HK1026138A1 (en) 2000-12-08
LV12449A (lv) 2000-04-20
PL190753B1 (pl) 2006-01-31
CA2278025C (en) 2005-09-06
US6368616B1 (en) 2002-04-09
HUP0002473A2 (hu) 2000-12-28
RS49701B (sr) 2007-12-31
ID21892A (id) 1999-08-05
KR20000070214A (ko) 2000-11-25
WO1998031343A2 (en) 1998-07-23
CZ237499A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
IL130979A0 (en) An aqueous suspension for nasal admnistration containing loteprednol etabonate and microcrystalline cellulose carmellose sodium
EP0747078A3 (en) Nasal mask
ZA964188B (en) Nasal applicator
AU3290595A (en) An aqueous nasal suspension
GB9505134D0 (en) Laryngeal mask airways
AU133091S (en) A nasal mask shell
GB2331932B (en) Laryngeal mask
IL117752A0 (en) Aqueous interferon solutions
HUP0000962A3 (en) Agriculturally usable, stable aqueous suspension containing a guanidine derivative, method for producing and using thereof
AU730196C (en) Aqueous suspension of loteprednol etabonate
GB9807310D0 (en) Laryngeal mask
GB9705585D0 (en) Laryngeal mask assemlies
EP1183076A4 (en) NASAL VENTILATION MASK WITH MINIMUM CONTACT AND THIS USING SYSTEM
PL319871A1 (en) Framework of control cabinet body
PL318132A1 (en) Aqueous preparations of risperidone
AU133090S (en) A nasal mask shell
GB9603555D0 (en) Laryngeal mask airways
PL335908A1 (en) Suspensions of cellulose ethers
AU9359798A (en) (nasal) breathing aid
GB2328878B (en) Medico-surgical tubes
HUP9601407A2 (en) Stabilisation for aqueous 3-iso-thiazolone solutions
GB9608255D0 (en) Nasal intubation
GB9720612D0 (en) Medico-surgical tubes
AU5102698A (en) Physiologically acceptable aqueous solutions and methods for their use
AU128435S (en) Nasal inhaler

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees